<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Evaluation and treatment of low bone mass in primary biliary cholangitis (primary biliary cirrhosis)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Evaluation and treatment of low bone mass in primary biliary cholangitis (primary biliary cirrhosis)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Evaluation and treatment of low bone mass in primary biliary cholangitis (primary biliary cirrhosis)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven Flamm, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Raoul Poupon, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Clifford J Rosen, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keith D Lindor, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 07, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatic osteodystrophy refers to the structural and metabolic bone changes seen in patients with chronic liver disease and includes both osteoporosis and osteomalacia. Osteoporosis is a skeletal condition characterized by low bone mass, whereas osteomalacia is a disorder of decreased bone mineralization of newly formed osteoid at sites of bone turnover. Both disorders increase the risk for fracture. (See
         <a class="medical medical_review" href="/z/d/html/2044.html" rel="external">
          "Pathogenesis of osteoporosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2040.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of osteomalacia in adults"
         </a>
         .)
        </p>
        <p>
         This topic will review the evaluation of low bone mass in patients with primary biliary cholangitis (previously referred to as primary biliary cirrhosis). The discussion that follows is generally consistent with guidelines regarding osteoporosis in patients with liver disease [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         Other related issues, including bone disease following liver transplantation and a discussion of treatment approaches for osteoporosis, are discussed elsewhere.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2043.html" rel="external">
          "Prevention and treatment of osteoporosis after solid organ or stem cell transplantation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3036135740">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Low bone density is common in patients with primary biliary cholangitis (PBC), with prevalence estimates ranging from 20 to 50 percent [
         <a href="#rid4">
          4-7
         </a>
         ]. In observational studies, age, weight, height, histologic stage, menopausal status, vitamin D deficiency, and severity and duration of liver damage were identified as risk factors for osteoporosis [
         <a href="#rid4">
          4,6,8-10
         </a>
         ]. Only 20 percent of patients with advanced stages of PBC have normal bone mass [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         The prevalence of fractures among patients with PBC is approximately 10 to 20 percent [
         <a href="#rid2">
          2,8
         </a>
         ]. When compared with the general population, the absolute increase in fracture risk is moderately increased. In a population-based study, patients with primary biliary cholangitis had a twofold increased risk of any fracture compared with the general population, with an absolute excess fracture rate of 12.5 per 1000 person-years [
         <a href="#rid12">
          12
         </a>
         ]. In one study, fractures were associated with bone density, menopause, age, and height but not with severity of PBC [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Osteomalacia, characterized by decreased bone mineralization, is rarely seen in PBC [
         <a href="#rid7">
          7
         </a>
         ]. When present, it is typically associated with vitamin D deficiency, with or without concomitant fat malabsorption. (See
         <a class="medical medical_review" href="/z/d/html/2040.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of osteomalacia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H332402697">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanism of osteoporosis in patients with primary biliary cholangitis is not well understood. The plasma concentration of calcium is usually normal. Patients with cholestatic liver disease may be at increased risk for malabsorption of fat-soluble vitamins due to decreased bile acid secretion, and deficiency of vitamin D is seen in approximately 15 to 30 percent of patients with PBC [
         <a href="#rid5">
          5,13
         </a>
         ]. However, chronic cholestasis leading to malabsorption of vitamin D does not fully explain bone disease in patients with primary biliary cholangitis (PBC) because the plasma concentrations of calcidiol (25-hydroxyvitamin D) and calcitriol (1,25 dihydroxyvitamin D) are normal in some patients with PBC and osteoporosis [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">
          "Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Defining vitamin D sufficiency'
         </a>
         .)
        </p>
        <p>
         Studies suggest that patients with PBC have low-turnover osteoporosis (bone resorption and formation reduced), possibly due to one or more of the following mechanisms [
         <a href="#rid7">
          7,14
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced levels of specific growth factors (eg, insulinlike growth factor 1) are seen in patients with cirrhosis and this negatively affects osteoblast function and bone formation [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unconjugated bilirubin or serum from jaundiced patients negatively affects osteoblast viability and differentiation in experimental models [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lithocholic acid impairs osteoblast activity and is associated with Vitamin K deficiency which also impairs osteoblast formation in experimental models [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The pathogenesis of osteoporosis is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2044.html" rel="external">
          "Pathogenesis of osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H332402908">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation for low bone mass in a patient with PBC is similar to that in any patient at risk for osteoporosis and includes assessment of clinical risk factors for fracture, bone mineral density testing, and laboratory evaluation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment", section on 'Assessment of fracture risk'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of osteoporosis in men"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4067436113">
         <span class="h2">
          Clinical risk factors for fracture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic liver disease, including PBC, is a risk factor for low bone density and fracture. Patients with PBC may have additional risk factors for fracture independent of bone mineral density and PBC  (
         <a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">
          table 1
         </a>
         ). Bone mineral density (BMD) and clinical risk factors combined may provide a better estimate of fracture risk than BMD or clinical risk factors alone. (See
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment", section on 'Clinical risk factor assessment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H668829321">
         <span class="h2">
          Bone mineral density testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of patients with osteoporosis do not have symptoms related to their bone disease. At the time of diagnosis of PBC, we obtain BMD testing in patients with PBC who have at least one additional risk factor for osteoporosis  (
         <a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef52724" href="/z/d/graphic/52724.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1,4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">
          "Screening for osteoporosis in postmenopausal women and men", section on 'Bone mineral density'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2056.html" rel="external">
          "Overview of dual-energy x-ray absorptiometry"
         </a>
         .)
        </p>
        <p>
         Osteoporosis in postmenopausal women and in men age 50 years and older is defined by a bone mineral density that is ≥2.5 standard deviations below the average value of young adults (T-score), whereas low bone mass is defined by a value more than one standard deviation but less than 2.5 standard deviations below the average  (
         <a class="graphic graphic_table graphicRef53999" href="/z/d/graphic/53999.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of osteoporosis in men"
         </a>
         .)
        </p>
        <p>
         In premenopausal women and in men under the age of 50 years, a clinical diagnosis of osteoporosis should not be made on the basis of BMD alone. Osteoporosis can be diagnosed when the bone density is below the expected range for age (Z-score ≤-2), in the presence of other risk factors for fracture (eg, PBC, long-term glucocorticoid use, hypogonadism). (See
         <a class="medical medical_review" href="/z/d/html/2058.html" rel="external">
          "Epidemiology and etiology of premenopausal osteoporosis", section on 'Definitions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of osteoporosis in men", section on 'Diagnosis of osteoporosis'
         </a>
         .)
        </p>
        <p>
         In addition, any patient with a fragility fracture is regarded as having osteoporosis. A fragility fracture is due to any fall that occurs from a standing height or less that results in a fracture, and common sites for fragility fracture are the hip, spine and wrist. The most common fractures are vertebral fractures, two-thirds of which are asymptomatic and are diagnosed as incidental findings on a chest or abdominal radiograph. (See
         <a class="medical medical_review" href="/z/d/html/7775.html" rel="external">
          "Osteoporotic thoracolumbar vertebral compression fractures: Clinical manifestations and treatment", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H58558900">
         <span class="h2">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         We obtain the following laboratory tests as part of the initial evaluation for low bone mass:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         25-hydroxyvitamin D (25[OH]D)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete biochemistry profile (including calcium, phosphate, alkaline phosphatase, creatinine)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testosterone in men
        </p>
        <p>
        </p>
        <p>
         Patients with osteoporosis usually have normal serum levels of calcium, phosphate, and alkaline phosphatase. Although 25-hydroxyvitamin D levels may be low in patients with osteoporosis, 25-hydroxyvitamin D levels rarely are below 10 ng/mL (25 nmol/L). Patients with serum 25(OH)D levels &lt;10 ng/mL are at risk for developing osteomalacia and require further evaluation. (See
         <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">
          "Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H4157474531">
         <span class="h2">
          Overall approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to the prevention and treatment of low bone mass in patients with primary biliary cholangitis depends upon factors such as the patient's bone mineral density, age, and whether the patient has hypogonadism  (
         <a class="graphic graphic_algorithm graphicRef52724" href="/z/d/graphic/52724.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Lifestyle measures should be adopted universally to reduce bone loss in patients with PBC. Lifestyle measures include adequate calcium and vitamin D, exercise, smoking cessation, counseling on fall prevention, and avoidance of heavy alcohol use.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">
          "Calcium and vitamin D supplementation in osteoporosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2659024686">
         <span class="h2">
          Patients who are candidates for pharmacologic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacologic therapy with a bisphosphonate is preferred for most patients with primary biliary cholangitis who have fragility fractures, osteoporosis on BMD, or who have T-scores between -1 and -2.5 and high risk for fracture. (See
         <a class="local">
          'Evaluation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment", section on 'Assessment of fracture risk'
         </a>
         .)
        </p>
        <p>
         The management of such patients is similar to that for other patients who have osteoporosis, and oral bisphosphonates are considered initial pharmacologic therapy for most patients at risk for fracture. Vitamin D deficiency should be corrected prior to initiation of bisphosphonates. (See
         <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">
          "Bisphosphonate therapy for the treatment of osteoporosis", section on 'Pretreatment evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/104424.html" rel="external">
          "Risks of bisphosphonate therapy in patients with osteoporosis"
         </a>
         .)
        </p>
        <p>
         Oral bisphosphonates should not be used as initial therapy in patients with esophageal disorders (eg, achalasia, esophageal stricture, esophageal varices, Barrett esophagus) or with an inability to follow the dosing requirements (eg, stay upright for at least 30 minutes). These patients can be treated instead with intravenous bisphosphonate therapy or other approved agents. Additional therapies for patients with contraindications to oral bisphosphonates are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Gastrointestinal malabsorption or difficulty with dosing requirements'
         </a>
         .)
        </p>
        <p>
         For patients with osteoporosis who are on therapy, we repeat BMD testing in two years. In a trial of 42 postmenopausal women with PBC with two year follow-up, improvements in bone mineral density were similar in women receiving weekly
         <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">
          alendronate
         </a>
         compared with monthly
         <a class="drug drug_general" data-topicid="8887" href="/z/d/drug information/8887.html" rel="external">
          ibandronate
         </a>
         (mean percentage change 4.5 versus 5.7 percent) [
         <a href="#rid18">
          18
         </a>
         ]. Neither treatment adversely affected liver function or cholestasis. Two small studies of oral bisphosphonate treatment in women with PBC have also suggested improvement in bone mineral density following approximately two years of treatment [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1806899883">
         <span class="h2">
          Patients not requiring pharmacologic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with PBC who do not have osteoporosis on initial testing or who do not have increased risk of fracture based on clinical risk assessment, we perform follow-up bone mineral density testing after two to three years, but acknowledge that data are lacking regarding the optimal testing interval [
         <a href="#rid1">
          1,21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3076927692">
         <span class="h2">
          Patients following liver transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with chronic liver disease who undergo liver transplantation may show improvement in bone mineral density in the long term [
         <a href="#rid22">
          22
         </a>
         ]. The management of osteoporosis in patients undergoing liver transplantation is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2043.html" rel="external">
          "Prevention and treatment of osteoporosis after solid organ or stem cell transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3908239332">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112041.html" rel="external">
          "Society guideline links: Primary biliary cholangitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Patients with primary biliary cholangitis (PBC) are at risk for osteoporosis and fracture for several reasons, including age, menopausal status, and cholestasis contributing to vitamin D deficiency. Low bone density is common in patients with PBC, with prevalence estimates ranging from 20 to 50 percent. When compared with the general population, the absolute increase in fracture risk is approximately twofold higher. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone mineral density testing
         </strong>
         – The majority of patients with osteoporosis do not have symptoms related to their bone disease. At the time of diagnosis of PBC, we obtain bone mineral density testing in patients with PBC who have at least one additional risk factor for osteoporosis  (
         <a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef52724" href="/z/d/graphic/52724.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Bone mineral density testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory testing
         </strong>
         – For all patients with PBC and low bone mass, we obtain the following laboratory tests as part of the initial evaluation (see
         <a class="local">
          'Laboratory tests'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         25-hydroxyvitamin D (25[OH]D)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complete biochemistry profile (including calcium, phosphate, alkaline phosphatase, creatinine)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complete blood count
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Testosterone in men
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The management of patients with PBC and osteoporosis is similar to that for other patients who have osteoporosis:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lifestyle measures should be adopted universally to reduce bone loss in patients with PBC. Lifestyle measures include adequate calcium and vitamin D, exercise, smoking cessation, counseling on fall prevention, and avoidance of heavy alcohol use. (See
         <a class="local">
          'Overall approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For most patients with PBC who have osteoporosis, pharmacologic therapy with a bisphosphonate is suggested. Oral bisphosphonates should not be used as therapy in patients with esophageal disorders (eg, esophageal varices) or with an inability to follow the dosing requirements (eg, stay upright for at least 30 minutes). These patients can be treated instead with intravenous bisphosphonate therapy. (See
         <a class="local">
          'Patients who are candidates for pharmacologic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           American Gastroenterological Association. American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology 2003; 125:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leslie WD, Bernstein CN, Leboff MS, American Gastroenterological Association Clinical Practice Commitee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindor KD, Bowlus CL, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2019; 69:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wariaghli G, Allali F, El Maghraoui A, Hajjaj-Hassouni N. Osteoporosis in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2010; 22:1397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet 2015; 386:1565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mounach A, Ouzzif Z, Wariaghli G, et al. Primary biliary cirrhosis and osteoporosis: a case-control study. J Bone Miner Metab 2008; 26:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glass LM, Su GL. Metabolic Bone Disease in Primary Biliary Cirrhosis. Gastroenterol Clin North Am 2016; 45:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guañabens N, Cerdá D, Monegal A, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010; 138:2348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menon KV, Angulo P, Weston S, et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001; 35:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liao CY, Chung CH, Chu P, et al. Increased risk of osteoporosis in patients with primary biliary cirrhosis. PLoS One 2018; 13:e0194418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006; 12:1390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solaymani-Dodaran M, Card TR, Aithal GP, West J. Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 2006; 131:1752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agmon-Levin N, Kopilov R, Selmi C, et al. Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease. Immunol Res 2015; 61:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pugliese N, Arcari I, Aghemo A, et al. Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges. World J Gastroenterol 2022; 28:1430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz-Gaspà S, Martinez-Ferrer A, Guañabens N, et al. Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology 2011; 54:2104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz-Gaspà S, Guañabens N, Enjuanes A, et al. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Invest 2010; 40:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koshihara Y, Hoshi K, Okawara R, et al. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. J Endocrinol 2003; 176:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guañabens N, Monegal A, Cerdá D, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology 2013; 58:2070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guañabens N, Parés A, Ros I, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98:2268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005; 42:762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamburg SM, Piers DA, van den Berg AP, et al. Bone mineral density in the long term after liver transplantation. Osteoporos Int 2000; 11:600.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3606 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12949737" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12949738" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : AGA technical review on osteoporosis in hepatic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30070375" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20926953" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Osteoporosis in patients with primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26364546" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18600405" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Primary biliary cirrhosis and osteoporosis: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27261902" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Metabolic Bone Disease in Primary Biliary Cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20178794" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11592591" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Bone disease in primary biliary cirrhosis: independent indicators and rate of progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29543880" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Increased risk of osteoporosis in patients with primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16933236" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Bone mineral density before and after OLT: long-term follow-up and predictive factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17087953" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Fracture risk in people with primary biliary cirrhosis: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25424577" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35582674" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21837749" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20055894" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Lithocholic acid downregulates vitamin D effects in human osteoblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12630919" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23686738" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14572578" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16175618" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12612917" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : AGA technical review on osteoporosis in gastrointestinal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11069194" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Bone mineral density in the long term after liver transplantation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
